Compare Cassava Sciences Inc (FLNA) vs ThredUp Inc (TDUP) Price & Performance

FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.

The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.

ThredUp (TDUP) trades at $2.35, up 5.86% today, with a bearish technical signal and mixed financials. Revenue grew to $310.81M in 2025, but net losses persist at -$20.21M, though margins improved. Recent news highlights a record Q2 2026 with 17% revenue growth but also a fraud investigation and lowered guidance, causing volatility. Cash flow turned positive in 2025 at $3.09M, but debt-to-asset ratios remain elevated.

Outlook is cautious; analyst consensus is 57% buy, but profitability challenges and legal risks weigh. The stock faces headwinds from promotional pressures and investor skepticism, though expansion into live shopping offers growth potential. Risks include sustained losses, competitive threats, and macroeconomic sensitivity.